McKinsey August 19, 2021

Europe may be catching up with the United States in biotech innovation and funding. Its overall score on the Biotech Innovation Index improved by 20 percent in 2015–17 and 2018–20.

McKinsey’s Biotech Innovation Index assesses innovation and funding in terms of four indicators: discovery (measured in numbers of patents and publications); translation (measured in numbers of new biotech companies and average amounts raised in early-stage financing); growth capital (measured in average amounts raised during late-stage funding and by IPOs and follow-on offerings on public markets); and impact (measured in numbers of products launched).

Europe’s overall score on the index improved by 20 percent in 2015–17 and 2018–20, compared with an improvement of 5 percent in the United States, although the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
Gilead bets on Xilio cancer drug as biotech restructures
Pfizer shifts creative to Publicis in latest marketing move
Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug
Joseph La Barge On The Challenges Of Advancing Gene Therapy, Finding The Right Support
Exact Sciences' posts positive data for its capsule-on-a-string test for esophageal cancer

Share This Article